Immunovia AB: 1 director

A director at Immunovia AB sold 587,532 shares at 2.200SEK and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Immunovia AB - Terminating coverage

ABGSC terminates coverage of Immunovia HOLD is our final recommendation SEK 100 is our final target price

Immunovia AB - Q2’21 report

Recent developments during and after the quarter Financials Share price implication

Immunovia AB - A valuation more in line with our view

A share price that better reflects the future challenges Challenges and opportunities ahead A valuation call: Upgrade to HOLD, TP to SEK 100 (94)

Immunovia AB - Validation study results

Validation study shows improvement but… …symptomatic controls not included In summary – we reiterate our SELL recommendation

Immunovia AB - Q4’20 report

No surprises in the report Timelines, guidance and sales ramp-up in focus Reimbursement outlook – still blurry

Powerpoint Sector Report -

Immunovia AB - PanFAM-1

PanFAM-1 update Reimbursement – The BIG challenge Next steps

Immunovia AB - Promising but early

Autoimmune study published in JPR However, early in its development… Promising but neutral to the share

Immunovia AB - Third time’s a charm

Third webinar to clear out the cobwebs Some question marks still remain Case confirmed - SELL

Talking Points - Balder: Starting to put the new money to work

Acquisition eliminates the dilution from the issue Best earnings growth but 15% discount to peers

Immunovia AB - Finding a way forward for its test

Verification study results guide our thinking Limited market potential for the largest indications Valuation does not reflect challenges ahead

Immunovia AB - Q3 report

Progressing according to plan Financials in the quarter Executing on finalizing the validation study

Immunovia AB - Added transparancy gives CEO a fresh start

Immunovia provides additional data Validation study will set the commercial parameters Conclusion

Immunovia AB - There should be more than just “Accuracy”

More data than just “Accuracy” is needed Transparent reporting of all data is important Webinar on Tuesday 3 November at 09:00 CET

Talking Points - Nordea: Q3’20: Moving in the right direction

Immunovia (Hold) Rec. change: Clouding our visibility ...has prompted us to raise our earnings estimates Reiterate BUY with a target price of SEK 81 (79)

Immunovia AB - Clouding our visibility

Analysis of Verification Study raises red flags US sales start delayed until late Q1’21 (prev. Q4’20) Down to HOLD (Buy) – risk-adj. TP SEK 210 (249)

Immunovia AB - Verification study: Sneak peek until full results

Verification study results in line with previous results First look at IMMray® in a locked state seems positive Important validation but we wait for more details

Immunovia AB - Edging closer to a commercial launch

Leading KOLs weigh in on Immunovia Key takeaways from experts We reiterate BUY and raise our TP to SEK 249 (217)

Immunovia AB - Q4’20 US launch target remains

Solid cost-control in an undramatic Q2-report Directed share issue to support launch activities All eyes on US out-of-pocket sales launch in Q4’20